Summary

The global biopharmaceutical process analytical technology market is projected to reach USD 4.32 billion by 2031 from USD 1.96 billion in 2026, at a CAGR of 17.1% from 2026 to 2031. The biopharmaceutical process analytical technology market is primarily driven by the increasing demand for real-time process monitoring and control to ensure consistent product quality, improve manufacturing efficiency, and comply with stringent regulatory requirements. The rapid growth of biologics, biosimilars, vaccines, and advanced therapies such as cell and gene therapies is accelerating the adoption of PAT solutions, including spectroscopy, chromatography, mass spectrometry, and process analyzers, to monitor critical process parameters (CPPs) and critical quality attributes (CQAs) throughout biomanufacturing. In addition, the widespread implementation of Quality-by-Design (QbD), continuous bioprocessing, and real-time release testing (RTRT), supported by regulatory agencies, is encouraging manufacturers to integrate advanced analytical technologies into production workflows. Furthermore, increasing investments in smart biomanufacturing, automation, artificial intelligence (AI), machine learning (ML), and digital manufacturing platforms are enhancing process optimization, reducing batch failures and production costs, and enabling predictive process control, thereby driving sustained growth of the biopharmaceutical PAT market. Liquid chromatography/HPLC account for the largest share of the biopharmaceutical process analytical technology market in 2025 By type, the biopharmaceutical process analytical technology market is segmented into liquid chromatography /HPLC, gas chromatography, mass spectrometry, next-generation sequencing, nuclear magnetic resonance spectroscopy, Raman spectroscopy, infrared spectroscopy, particle counters & imaging, differential light scattering, and other techniques. The liquid chromatography/high-performance liquid chromatography (HPLC) segment is experiencing significant growth in the biopharmaceutical process analytical technology (PAT) market due to the increasing need for precise analysis and monitoring of complex biologics throughout the manufacturing process. HPLC is widely used to characterize proteins, monoclonal antibodies, peptides, vaccines, and other biologics by detecting impurities, monitoring critical quality attributes (CQAs), and ensuring batch-to-batch consistency. The growing adoption of biologics, biosimilars, and cell and gene therapies, coupled with stringent regulatory requirements emphasizing Quality-by-Design (QbD) and real-time process control, is driving demand for advanced HPLC systems. Furthermore, continuous advancements in ultra-high-performance liquid chromatography (UHPLC), automated sampling, multidimensional chromatography, and integration with mass spectrometry (LC-MS) are improving analytical speed, sensitivity, and throughput. These innovations, along with increasing investments in continuous bioprocessing and digital biomanufacturing, are reinforcing the role of HPLC as a critical analytical technology within modern biopharmaceutical PAT workflows. The analyzers accounted for the largest share of the biopharmaceutical process analytical technology market By product type, the biopharmaceutical process analytical technology market is segmented into analyzers, sensors & probes, samples, and software. The analyzers segment is expected to register strong growth in the biopharmaceutical process analytical technology (PAT) market due to the rising demand for real-time monitoring of critical process parameters (CPPs) and critical quality attributes (CQAs) throughout biopharmaceutical manufacturing. Advanced analyzers, including Raman, near-infrared (NIR), FTIR, UV-Vis spectroscopic analyzers, chromatography systems, mass spectrometers, and particle analyzers, enable continuous process monitoring, improve process efficiency, and ensure consistent product quality while meeting stringent regulatory requirements. The increasing production of biologics, biosimilars, vaccines, and advanced therapies, along with the growing adoption of continuous bioprocessing, Quality-by-Design (QbD), and real-time release testing (RTRT), is accelerating demand for sophisticated analytical instruments. Additionally, the integration of analyzers with automation, artificial intelligence (AI), machine learning (ML), Manufacturing Execution Systems (MES), and cloud-based analytics is enabling predictive process control, minimizing batch failures, reducing operational costs, and supporting the transition toward smart biopharmaceutical manufacturing. The online mode accounted for the largest share of the biopharmaceutical process analytical technology market. The online mode segment is witnessing robust growth in the biopharmaceutical process analytical technology (PAT) market due to the increasing adoption of continuous bioprocessing and the need for real-time monitoring of critical process parameters (CPPs) and critical quality attributes (CQAs) without interrupting production. Online mode systems provide continuous analytical data during upstream and downstream manufacturing, enabling rapid detection of process deviations, improved process control, enhanced product consistency, and reduced batch failures. The growing implementation of Quality-by-Design (QbD), real-time release testing (RTRT), and regulatory initiatives promoting data-driven manufacturing is further accelerating the deployment of online PAT solutions. In addition, advancements in spectroscopy, chromatography, biosensors, automation, artificial intelligence (AI), and Manufacturing Execution Systems (MES) are improving predictive process control and operational efficiency, making online mode technologies an essential component of modern, digital biopharmaceutical manufacturing. By application, vaccines accounted for the largest share in the forecasted period. By application, the biopharmaceutical process analytical technology (PAT) market is segmented into vaccines, cell & gene therapy, biosimilars & biologics, hormonal therapy, and other applications. The vaccines application segment is driving growth in the biopharmaceutical process analytical technology (PAT) market due to the increasing global demand for safe, high-quality, and rapidly manufactured vaccines. PAT solutions enable real-time monitoring of critical process parameters (CPPs) and critical quality attributes (CQAs) throughout vaccine production, helping manufacturers improve process efficiency, ensure batch-to-batch consistency, and meet stringent regulatory requirements. Rising investments in the development and production of conventional and next-generation vaccines, including mRNA, viral vector, recombinant protein, and combination vaccines, are accelerating the adoption of advanced analytical technologies such as spectroscopy, chromatography, mass spectrometry, and biosensors. Additionally, the expansion of vaccine manufacturing capacity, increasing emphasis on pandemic preparedness, and the growing implementation of Quality-by-Design (QbD), continuous bioprocessing, and real-time release testing (RTRT) are further driving the demand for PAT solutions to optimize production, reduce manufacturing risks, and enhance overall product quality. The Asia Pacific market is projected to show the highest growth rate in the biopharmaceutical process analytical technology (PAT) market. The biopharmaceutical process analytical technology (PAT) market spans five primary regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific biopharmaceutical process analytical technology (PAT) market is witnessing rapid growth, driven by the expansion of biologics, biosimilars, vaccines, and cell and gene therapy manufacturing across China, India, Japan, South Korea, and Singapore. A key recent trend is the increasing deployment of AI-enabled PAT platforms, digital twins, single-use sensors, cloud-based analytics, and continuous bioprocessing to enable real-time monitoring and predictive process control. Governments and private organizations are making substantial investments in advanced biomanufacturing infrastructure, while contract development and manufacturing organizations (CDMOs) are embedding PAT into new greenfield facilities to meet global regulatory standards and accelerate technology transfer. In addition, the adoption of Quality-by-Design (QbD), real-time release testing (RTRT), and Industry 4.0-enabled smart manufacturing is driving demand for advanced analytical technologies such as spectroscopy, chromatography, mass spectrometry, and process analyzers, positioning Asia Pacific as the fastest-growing regional market for biopharmaceutical PAT solutions. A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1 (30%), Tier 2 (40%), and Tier 3 (30%) • By Designation: Managers (30%), Directors (10%), and Others (60%) • By Region: North America (22%), Europe (22%), Asia Pacific (45%), Latin America (5%), and RoW (11%) The major players in the biopharmaceutical process analytical technology (PAT) market include Agilent Technologies (US), Thermo Fisher Scientific Inc (US), Shimadzu Corporation (Japan), Waters Corporation (US), Danaher Corporation (US), among others among others. Research Coverage The research report examines the biopharmaceutical process analytical technology (PAT) market by type, product type, mode, application, end-users, and geography. This research covers factors that are driving market expansion, analyzes prospects and parameters faced by industries in the present time, and provides specifics on the competitive landscape considering market leaders and small and medium enterprises. This research also estimates the revenue of different market segments by considering five regions and micro-market analysis. Reasons to Buy the Report The report will provide market leaders and new entrants with valuable information regarding the revenue estimates for the overall biopharmaceutical process analytical technology (PAT) market and its subsegments. It will help stakeholders understand the competitive landscape, allowing them to position their businesses more effectively and develop appropriate go-to-market strategies. Additionally, the report offers insights into the market dynamics, including key drivers, restraints, challenges, and opportunities. This report provides insightful data on the following pointers: • Market Penetration: In-depth coverage of product portfolios offered by the top players in the biopharmaceutical process analytical technology (PAT) market • Product Development/Innovation: In-depth coverage of product portfolios offered by the top players in the biopharmaceutical process analytical technology (PAT) market • Market Development: Insightful data on profitable developing areas • Market Diversification: Details about recent developments and advancements in the biopharmaceutical process analytical technology (PAT) market • Competitive Assessment: Extensive assessment of the products, growth tactics, revenue projections, and market categories of the top competitors

ページTOPに戻る

Table of Contents

1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.3 STUDY SCOPE 25
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 25
1.3.2 INCLUSIONS & EXCLUSIONS 26
1.3.3 YEARS CONSIDERED 27
1.3.4 CURRENCY CONSIDERED 27
1.4 STAKEHOLDERS 27
1.5 SUMMARY OF CHANGES 28
2 EXECUTIVE SUMMARY 29
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 29
2.2 DISRUPTIVE TRENDS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL
TECHNOLOGY MARKET 31
2.2.1 HIGH GROWTH SEGMENTS 32
2.3 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 33
3 PREMIUM INSIGHTS 34
3.1 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET OVERVIEW 34
3.2 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2026 VS. 2031 (USD MILLION) 35
3.3 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE & COUNTRY (2025) 36
3.4 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET:
GEOGRAPHIC GROWTH OPPORTUNITIES 37
3.5 REGIONAL MIX: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, 2024–2031 (USD MILLION) 38
4 MARKET OVERVIEW 39
4.1 INTRODUCTION 39
4.2 MARKET DYNAMICS 40
4.2.1 DRIVERS 40
4.2.1.1 Expansion of biologics and increasingly complex biomanufacturing processes 40
4.2.1.2 Convergence of artificial intelligence and digital twins with spectroscopic PAT hardware 41
4.2.1.3 Rising adoption of continuous and intensified bioprocessing 41
4.2.2 RESTRAINTS 42
4.2.2.1 Persistent shortage of skilled bioprocess and data science professionals 42
4.2.2.2 High capital costs and integration complexity of retrofitting legacy infrastructure 42
4.2.3 OPPORTUNITIES 43
4.2.3.1 Commercialization of disposable and low-volume PAT sensors 43
4.2.3.2 New installed base created by biomanufacturing capacity expansion in Asia Pacific 43
4.2.4 CHALLENGES 44
4.2.4.1 Ensuring data integrity, cybersecurity, and reliable contingency controls 44
4.2.4.2 Absence of fully harmonized global standards for PAT method validation 44
5 INDUSTRY TRENDS 46
5.1 PORTER’S FIVE FORCES ANALYSIS 46
5.1.1 BARGAINING POWER OF BUYERS 47
5.1.2 BARGAINING POWER OF SUPPLIERS 47
5.1.3 THREAT OF NEW ENTRANTS 47
5.1.4 THREAT OF SUBSTITUTES 47
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 47
5.2 MACROECONOMIC INDICATORS 48
5.2.1 GDP TRENDS AND FORECAST 48
5.2.2 TRENDS IN GLOBAL BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY 49
5.3 SUPPLY CHAIN ANALYSIS 49
5.3.1 MANUFACTURERS 50
5.3.2 SALES & DISTRIBUTION 50
5.3.3 END USERS 50
5.4 VALUE CHAIN ANALYSIS 51
5.4.1 RESEARCH & DEVELOPMENT 52
5.4.2 RAW MATERIAL PROCUREMENT 52
5.4.3 MANUFACTURING 52
5.4.4 DISTRIBUTION 52
5.4.5 MARKETING AND SALES 52
5.4.6 POST-SALE SERVICES 53
5.5 ECOSYSTEM ANALYSIS 53
5.6 PRICING ANALYSIS 53
5.6.1 AVERAGE SELLING PRICE OF PRODUCT, BY KEY PLAYERS, 2023-2025 (USD) 54
5.6.2 AVERAGE SELLING PRICE TREND, BY REGION, 2025 54
5.7 TRADE ANALYSIS 56
5.7.1 IMPORT DATA FOR HS CODE 902720 56
5.7.2 IMPORT DATA FOR CHROMATOGRAPHS AND ELECTROPHORESIS INSTRUMENTS (HS CODE 902720) 57
5.7.3 EXPORT SCENARIO FOR HS CODE 902720 57
5.7.4 EXPORT DATA FOR CHROMATOGRAPHS AND ELECTROPHORESIS INSTRUMENTS (HS CODE 902720) 58
5.8 KEY CONFERENCES & EVENTS, 2026–2027 58
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 59
5.9.1 AI-DRIVEN DIGITAL TRANSFORMATION AND EXPANDING APPLICATION LANDSCAPE IN BPAT MARKET 59
5.10 INVESTMENT & FUNDING SCENARIO 60
5.11 CASE STUDY ANALYSIS 62
5.11.1 CASE STUDY 62
5.12 IMPACT OF 2025 US TARIFF ON BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET 63
5.12.1 INTRODUCTION 63
5.12.2 KEY TARIFF RATES 64
5.12.3 PRICE IMPACT ANALYSIS 65
5.12.4 IMPACT ON COUNTRY/REGION 65
5.12.4.1 US 65
5.12.4.2 Europe 65
5.12.4.3 Asia Pacific 66
5.12.5 IMPACT ON END-USE INDUSTRIES 66
6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL,
AND AI ADOPTION 67
6.1 KEY EMERGING TECHNOLOGIES 67
6.1.1 ADVANCED RAMAN AND NEAR-INFRARED SPECTROSCOPY 67
6.1.2 ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING-BASED SOFT SENSORS 67
6.2 COMPLEMENTARY TECHNOLOGIES 67
6.2.1 QUALITY BY DESIGN AND DESIGN OF EXPERIMENTS SOFTWARE 67
6.2.2 MES, LIMS, AND ELECTRONIC BATCH RECORDS 67
6.2.3 PROCESS AUTOMATION AND ADVANCED PROCESS CONTROL 67
6.3 PATENT ANALYSIS 68
6.4 IMPACT OF AI/GEN AI ON BIOPHARMACEUTICAL PROCESS ANALYTICAL
TECHNOLOGY MARKET 69
6.4.1 TOP USE CASES AND MARKET POTENTIAL 69
6.4.2 BEST PRACTICES IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY 70
6.4.3 CASE STUDIES OF AI IMPLEMENTATION IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET 70
6.4.4 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 72
6.4.5 CLIENTS' READINESS TO ADOPT AI IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET 72
6.5 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 73
7 REGULATORY ANALYSIS 74
7.1 REGULATORY LANDSCAPE 74
7.1.1 KEY REGULATORY GUIDELINES 74
7.1.1.1 US 74
7.1.1.2 Europe 74
7.1.1.3 Asia Pacific 75
7.1.2 KEY REGULATORY BODIES & GOVERNMENT AGENCIES 76
8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR 79
8.1 DECISION MAKING PROCESS 79
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 79
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 80
8.2.2 KEY BUYING CRITERIA 81
8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 82
8.4 UNMET NEEDS FROM VARIOUS END USERS 82
9 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY TYPE 84
9.1 INTRODUCTION 85
9.2 LIQUID CHROMATOGRAPHY/HPLC 86
9.2.1 COMPLEX BIOLOGICS AND OLIGONUCLEOTIDE THERAPEUTICS ACCELERATE ADOPTION 86
9.3 GAS CHROMATOGRAPHY 87
9.3.1 GROWING ADOPTION FOR REAL-TIME PROCESS MONITORING IN BIOPHARMACEUTICAL MANUFACTURING 87
9.4 MASS SPECTROMETRY 88
9.4.1 HIGHER-RESOLUTION, NATIVE, AND AI-INTEGRATED MASS SPECTROMETRY PLATFORMS ENHANCE BIOTHERAPEUTIC CHARACTERIZATION 88
9.5 REAL-TIME PCR/QPCR 89
9.5.1 CELL AND GENE THERAPY RELEASE TESTING NEEDS DRIVE RAPID EXPANSION OF DIGITAL AND REAL-TIME PCR PLATFORMS 89
9.6 NEXT-GENERATION SEQUENCING 90
9.6.1 GROWING ADOPTION OF NGS FOR CELL & GENE THERAPY PROCESS MONITORING AND LOT RELEASE TESTING 90
9.7 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 91
9.7.1 GROWING ADOPTION OF NGS FOR CELL & GENE THERAPY PROCESS MONITORING AND LOT RELEASE TESTING 91
9.8 RAMAN SPECTROSCOPY 92
9.8.1 AI-ENHANCED RAMAN ANALYTICS ADVANCE TECHNIQUE TO CENTRAL REAL-TIME BIOPROCESS CONTROL TECHNOLOGY 92
9.9 INFRARED SPECTROSCOPY 93
9.9.1 GROWING INTEGRATION OF NIR SPECTROSCOPY INTO CONTINUOUS BIOMANUFACTURING FOR REAL-TIME PROCESS MONITORING 93
9.10 PARTICLE COUNTERS & IMAGING 94
9.10.1 GROWING REGULATORY SCRUTINY OF SUBVISIBLE PARTICULATES DRIVES ADOPTION 94
9.11 DIFFERENTIAL LIGHT SCATTERING 95
9.11.1 GROWING ADOPTION FOR EARLY PROTEIN AND LNP AGGREGATION DETECTION 95
9.12 OTHER TYPES 96
10 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY PRODUCT TYPE 98
10.1 INTRODUCTION 99
10.2 ANALYZERS 99
10.2.1 GROWING ADOPTION OF REAL-TIME, MULTI-PARAMETER ANALYZERS
FOR AI-ENABLED BIOPHARMACEUTICAL PAT 99
10.3 SENSORS & PROBES 100
10.3.1 INCREASING ADOPTION FOR REAL-TIME PROCESS CONTROL IN BIOPHARMACEUTICAL MANUFACTURING 100
10.4 SAMPLES 101
10.4.1 GROWING ADOPTION OF AUTOMATED ASEPTIC SAMPLERS FOR REAL-TIME BIOPROCESS MONITORING 101
10.5 SOFTWARE 102
10.5.1 AI-ENABLED CHEMOMETRICS AND DIGITAL TWIN TECHNOLOGIES ACCELERATE BIOPHARMACEUTICAL PAT ADOPTION 102
11 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY MODE 104
11.1 INTRODUCTION 105
11.2 ONLINE 105
11.2.1 INCREASING USE OF ONLINE PAT PLATFORMS FOR CONTINUOUS QUALITY MONITORING AND REGULATORY COMPLIANCE 105
11.3 OFFLINE MODE 106
11.3.1 GROWING ADOPTION OF MULTI-ATTRIBUTE METHODS AND BIO-INERT UHPLC PLATFORMS FOR OFFLINE QUALITY CONTROL 106
11.4 AT-LINE 107
11.4.1 GROWING ADOPTION FOR RAPID BIOPROCESS MONITORING AND QUALITY CONTROL 107
11.5 IN-LINE 108
11.5.1 GROWING ADOPTION OF IN-LINE PAT SYSTEMS FOR CONTINUOUS REAL-TIME BIOPROCESS MONITORING 108
12 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY APPLICATION 110
12.1 INTRODUCTION 111
12.2 VACCINES 111
12.2.1 RISING BIOPHARMA INVESTMENTS AND BIOLOGICS DEVELOPMENT TO DRIVE MARKET 111
12.3 CELL & GENE THERAPY 113
12.3.1 INCREASING INVESTMENTS IN CELL AND GENE THERAPY MANUFACTURING DRIVES SEGMENT 113
12.4 BIOSIMILARS & BIOLOGICS 114
12.4.1 GROWING BIOLOGICS MANUFACTURING INVESTMENTS AND BIOSIMILAR PRODUCTION AGREEMENTS – KEY DRIVERS 114
12.5 HORMONAL THERAPY 115
12.5.1 EXPANDING HORMONE MANUFACTURING CAPACITY DRIVES ADOPTION 115
12.6 OTHER APPLICATIONS 116
13 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY REGION 117
13.1 INTRODUCTION 118
13.2 NORTH AMERICA 119
13.2.1 US 122
13.2.1.1 AI-enabled analytical technologies accelerate market growth 122
13.2.2 CANADA 123
13.2.2.1 Expansion of bio-manufacturing capacity drives market 123
13.3 EUROPE 125
13.3.1 GERMANY 127
13.3.1.1 Continuous bioprocessing drives demand for integrated PAT technologies 127
13.3.2 UK 128
13.3.2.1 Growing adoption of advanced analytical instrumentation boosts PAT implementation 128
13.3.3 FRANCE 130
13.3.3.1 Advanced smart biomanufacturing through modular PAT integration to boost growth 130
13.3.4 ITALY 131
13.3.4.1 Expanding CDMO capabilities and advanced biomanufacturing accelerate PAT adoption 131
13.3.5 SPAIN 132
13.3.5.1 Expanding biologics manufacturing and bioprocess innovation accelerate PAT adoption 132
13.3.6 REST OF EUROPE 134
13.4 ASIA PACIFIC 135
13.4.1 JAPAN 138
13.4.1.1 Advanced chromatography and electrophoresis technologies accelerate market growth 138
13.4.2 CHINA 139
13.4.2.1 Regulatory harmonization and biopharmaceutical expansion accelerate PAT adoption 139
13.4.3 INDIA 140
13.4.3.1 Expanding biopharmaceutical manufacturing and CDMO capabilities accelerate PAT adoption 140
13.4.4 AUSTRALIA 142
13.4.4.1 Growing adoption of PAT driven by real-time process monitoring, regulatory compliance, and digital biomanufacturing 142
13.4.5 SOUTH KOREA 143
13.4.5.1 Advanced biologics manufacturing accelerates PAT implementation 143
13.4.6 REST OF ASIA PACIFIC 144
13.5 LATIN AMERICA 145
13.5.1 BRAZIL 148
13.5.1.1 Regulatory harmonization and biologics expansion drive market growth 148
13.5.2 MEXICO 149
13.5.2.1 Manufacturing expansion and investments spur PAT Adoption in biopharmaceuticals 149
13.5.3 REST OF LATIN AMERICA 151
13.6 MIDDLE EAST & AFRICA 152
13.6.1 GCC COUNTRIES 154
13.6.1.1 Vision 2030 and biotechnology investments accelerate biopharmaceutical PAT adoption 154
13.6.2 REST OF MIDDLE EAST & AFRICA 156
13.6.2.1 Local biopharmaceutical manufacturing and regulatory harmonization accelerate PAT adoption 156
14 COMPETITIVE LANDSCAPE 157
14.1 INTRODUCTION 157
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 157
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET 158
14.3 REVENUE ANALYSIS, 2022–2025 159
14.4 MARKET SHARE ANALYSIS, 2025 160
14.5 MARKET RANKING ANALYSIS, 2025 162
14.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 163
14.6.1 STARS 163
14.6.2 EMERGING LEADERS 163
14.6.3 PERVASIVE PLAYERS 163
14.6.4 PARTICIPANTS 163
14.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 165
14.6.5.1 Company footprint 165
14.6.5.2 Region footprint 166
14.6.5.3 Type footprint part 1 167
14.6.5.4 Type footprint part 2 168
14.6.5.5 Product type footprint 169
14.6.5.6 Mode footprint 170
14.6.5.7 Application footprint 171
14.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 172
14.7.1 PROGRESSIVE COMPANIES 172
14.7.2 RESPONSIVE COMPANIES 172
14.7.3 DYNAMIC COMPANIES 172
14.7.4 STARTING BLOCKS 172
14.7.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2025 174
14.7.5.1 Detailed list of key startups/SMEs 174
14.7.5.2 Competitive benchmarking of key startups/SMEs 175
14.8 COMPETITIVE SCENARIO 176
14.8.1 PRODUCT LAUNCHES & APPROVALS 176
14.8.2 DEALS 177
14.8.3 EXPANSIONS 178
14.9 COMPANY VALUATION & FINANCIAL METRICS 179
14.10 BRAND/PRODUCT COMPARISON 180
15 COMPANY PROFILES 181
15.1 KEY PLAYERS 181
15.1.1 WATERS CORPORATION 181
15.1.1.1 Business overview 181
15.1.1.2 Products offered 182
15.1.1.3 Recent developments 183
15.1.1.3.1 Product Launches 183
15.1.1.3.2 Deals 183
15.1.1.3.3 Expansions 183
15.1.1.4 MnM view 184
15.1.1.4.1 Right to win 184
15.1.1.4.2 Strategic choices 184
15.1.1.4.3 Weaknesses and competitive threats 184
15.1.2 DANAHER CORPORATION 185
15.1.2.1 Business overview 185
15.1.2.2 Products offered 186
15.1.2.3 Recent developments 187
15.1.2.3.1 Deals 187
15.1.2.3.2 Expansions 187
15.1.2.4 MnM view 187
15.1.2.4.1 Right to win 187
15.1.2.4.2 Strategic choices 188
15.1.2.4.3 Weaknesses and competitive threats 188
15.1.3 THERMO FISHER SCIENTIFIC INC 189
15.1.3.1 Business overview 189
15.1.3.2 Products offered 190
15.1.3.3 Recent developments 191
15.1.3.3.1 Product Launches 191
15.1.3.3.2 Deals 192
15.1.3.3.3 Expansions 193
15.1.3.4 MnM view 193
15.1.3.4.1 Right to win 193
15.1.3.4.2 Strategic choices 194
15.1.3.4.3 Weaknesses and competitive threats 194
15.1.4 AGILENT TECHNOLOGIES, INC 195
15.1.4.1 Business overview 195
15.1.4.2 Products offered 196
15.1.4.3 Recent developments 197
15.1.4.3.1 Product Launches 197
15.1.4.3.2 Deals 197
15.1.4.3.3 Expansions 198
15.1.4.4 MnM view 199
15.1.4.4.1 Right to win 199
15.1.4.4.2 Strategic choices 199
15.1.4.4.3 Weaknesses and competitive threats 199
15.1.5 SHIMADZU CORPORATION 200
15.1.5.1 Business overview 200
15.1.5.2 Products offered 201
15.1.5.3 Recent developments 202
15.1.5.3.1 Deals 203
15.1.5.3.2 Expansions 203
15.1.5.4 MnM view 203
15.1.5.4.1 Right to win 203
15.1.5.4.2 Strategic choices 204
15.1.5.4.3 Weaknesses and competitive threats 204
15.1.6 BRUKER CORPORATION 205
15.1.6.1 Business overview 205
15.1.6.2 Products offered 206
15.1.6.3 Recent developments 207
15.1.6.3.1 Product Launches 207
15.1.6.3.2 Deals 208
15.1.6.3.3 Expansions 208
15.1.7 METTLER TOLEDO 209
15.1.7.1 Business overview 209
15.1.7.2 Products offered 210
15.1.7.3 Recent developments 211
15.1.7.3.1 Deals 211
15.1.8 CARL ZEISS AG (ZEISS GROUP) 212
15.1.8.1 Business overview 212
15.1.8.2 Products offered 213
15.1.8.3 Recent developments 214
15.1.8.3.1 Deals 214
15.1.9 PERKINELMER. 215
15.1.9.1 Business overview 215
15.1.9.2 Products offered 216
15.1.9.3 Recent developments 217
15.1.9.3.1 Product Launches 217
15.1.9.3.2 Deals 217
15.1.10 EMERSON ELECTRIC CO 218
15.1.10.1 Business overview 218
15.1.10.2 Products offered 219
15.1.10.3 Recent developments 220
15.1.10.3.1 Product launches 220
15.1.11 ABB 221
15.1.11.1 Business overview 221
15.1.11.2 Products offered 222
15.1.11.3 Recent developments 223
15.1.11.3.1 Expansions 223
15.1.12 SARTORIUS AG 224
15.1.12.1 Business overview 224
15.1.12.2 Products offered 225
15.1.12.3 Recent developments 226
15.1.12.3.1 Deals 226
15.1.12.3.2 Expansions 227
15.1.13 MERCK KGAA 228
15.1.13.1 Business overview 228
15.1.13.2 Products offered 229
15.1.13.3 Recent developments 230
15.1.13.3.1 Deals 230
15.1.14 VERUM ANALYTICS 231
15.1.14.1 Business overview 231
15.1.14.2 Products offered 231
15.1.15 PROCESS INSIGHTS, INC 232
15.1.15.1 Business overview 232
15.1.15.2 Products offered 232
15.2 OTHER PLAYERS 233
15.2.1 HAMILTON COMPANY 233
15.2.2 ENDRESS+HAUSER GROUP SERVICES AG 234
15.2.3 VIAVI SOLUTIONS INC 235
15.2.4 METROHM AG 236
15.2.5 CONTROL DEVELOPMENT, INC 237
15.2.6 SCHMIDT + HAENSCH 238
15.2.7 SENSUM D.O.O. 239
15.2.8 AMETEK, INC 240
15.2.9 NECI. 241
15.2.10 SENTRONIC GMBH 242
16 RESEARCH METHODOLOGY 243
16.1 RESEARCH APPROACH 243
16.1.1 SECONDARY RESEARCH 244
16.1.2 PRIMARY RESEARCH 245
16.1.2.1 Breakdown of primaries 247
16.2 MARKET SIZE ESTIMATION 248
16.2.1 BOTTOM-UP APPROACH 249
16.2.1.1 Approach 1: Company revenue estimation approach 250
16.2.1.2 Approach 2: Customer-based market estimation 251
16.2.1.3 Growth forecast 252
16.3 DATA TRIANGULATION APPROACH 252
16.4 MARKET SHARE ESTIMATION 254
16.5 STUDY ASSUMPTIONS 254
16.6 RISK ASSESSMENT 255
16.6.1 RISK ASSESSMENT: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY (PAT) MARKET 255
16.7 GROWTH RATE ASSUMPTIONS 255
17 APPENDIX 256
17.1 DISCUSSION GUIDE 256
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 261
17.3 CUSTOMIZATION OPTIONS 263
17.4 RELATED REPORTS 263
17.5 AUTHOR DETAILS 264

ページTOPに戻る

List of Tables/Graphs

TABLE 1 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY (PAT) MARKET: INCLUSIONS & EXCLUSIONS 26.
TABLE 2 IMPACT OF PORTER’S FIVE FORCES ON BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET 46.
TABLE 3 AVERAGE SELLING PRICE OF PRODUCT, BY KEY PLAYERS, 2023-2025 (USD) 54.
TABLE 4 AVERAGE SELLING PRICE OF BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGIES MARKET, BY REGION (USD THOUSAND) 55.
TABLE 5 IMPORT DATA FOR CHROMATOGRAPHS AND ELECTROPHORESIS INSTRUMENTS (HS CODE 902720), BY COUNTRY, 2021–2025 (USD MILLION) 57.
TABLE 6 EXPORT DATA FOR CHROMATOGRAPHS AND ELECTROPHORESIS INSTRUMENTS (HS CODE 902720) 58.
TABLE 7 LIST OF MAJOR CONFERENCES AND EVENTS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, SEPTEMBER 2026–DECEMBER 2027 58.
TABLE 8 CASE STUDY 1: APPLICATION OF RAMAN MICROSCOPY IN PHARMACEUTICAL ANALYSIS 62.
TABLE 9 CASE STUDY 2: AMGEN RAMAN SPECTROSCOPY AND DEEP LEARNING FOR CONTINUOUS GLUCOSE CONTROL 62.
TABLE 10 US ADJUSTED RECIPROCAL TARIFF RATES 63.
TABLE 11 CASE STUDY 1: REAL-TIME PAT MONITORING OF DOWNSTREAM BIOPROCESSES 70.
TABLE 12 CASE STUDY 2: RAMAN-BASED CONTINUOUS BIOREACTOR MONITORING 71.
TABLE 13 CASE STUDY 3: REAL-TIME MONITORING OF SUCROSE VOLUME EXCLUSION DURING UF/DF 71.
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76.
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76.
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77.
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78.
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78.
TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT TYPE 81.
TABLE 20 KEY BUYING CRITERIA FOR BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY, BY PRODUCT TYPE 81.
TABLE 21 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 85.
TABLE 22 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 86.
TABLE 23 LIQUID CHROMATOGRAPHY/HPLC MARKET, BY REGION, 2024–2031 (USD MILLION) 87.
TABLE 24 GAS CHROMATOGRAPHY MARKET, BY REGION, 2024–2031 (USD MILLION) 88.
TABLE 25 MASS SPECTROMETRY MARKET, BY REGION, 2024–2031 (USD MILLION) 89.
TABLE 26 REAL-TIME PCR/QPCR MARKET, BY REGION, 2024–2031 (USD MILLION) 90.
TABLE 27 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION) 91.
TABLE 28 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY MARKET, BY REGION, 2024–2031 (USD MILLION) 92.
TABLE 29 RAMAN SPECTROSCOPY MARKET, BY REGION, 2024–2031 (USD MILLION) 93.
TABLE 30 INFRARED SPECTROSCOPY MARKET, BY REGION, 2024–2031 (USD MILLION) 94.
TABLE 31 PARTICLE COUNTERS & IMAGING MARKET, BY REGION, 2024–2031 (USD MILLION) 95.
TABLE 32 DIFFERENTIAL LIGHT SCATTERING MARKET, BY REGION, 2024–2031 (USD MILLION) 96.
TABLE 33 OTHER BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY TYPES MARKET, BY REGION, 2024–2031 (USD MILLION) 97.
TABLE 34 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 99.
TABLE 35 ANALYZERS: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 100.
TABLE 36 SENSORS & PROBES: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 101.
TABLE 37 SAMPLERS: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 102.
TABLE 38 SOFTWARE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 103.
TABLE 39 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2024–2031 (USD MILLION) 105.
TABLE 40 ONLINE BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 106.
TABLE 41 OFFLINE BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 107.
TABLE 42 AT-LINE BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 108.
TABLE 43 IN-LINE BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 109.
TABLE 44 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 111.
TABLE 45 VACCINES: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 112.
TABLE 46 CELL & GENE THERAPY: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 113.
TABLE 47 BIOSIMILARS & BIOLOGICS: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 114.
TABLE 48 HORMONAL THERAPY: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 115.
TABLE 49 OTHER APPLICATIONS: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 116.
TABLE 50 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 118.
TABLE 51 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 120.
TABLE 52 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 121.
TABLE 53 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 121.
TABLE 54 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2024–2031 (USD MILLION) 122.
TABLE 55 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 122.
TABLE 56 US: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 123.
TABLE 57 CANADA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 124.
TABLE 58 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125.
TABLE 59 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 126.
TABLE 60 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 126.
TABLE 61 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2024–2031 (USD MILLION) 127.
TABLE 62 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 127.
TABLE 63 GERMANY: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 128.
TABLE 64 UK: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 129.
TABLE 65 FRANCE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 131.
TABLE 66 ITALY: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 132.
TABLE 67 SPAIN: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 133.
TABLE 68 REST OF EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 134.
TABLE 69 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136.
TABLE 70 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 136.
TABLE 71 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 137.
TABLE 72 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2024–2031 (USD MILLION) 137.
TABLE 73 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 138.
TABLE 74 JAPAN: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 139.
TABLE 75 CHINA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 140.
TABLE 76 INDIA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 141.
TABLE 77 AUSTRALIA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 142.
TABLE 78 SOUTH KOREA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 144.
TABLE 79 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 145.
TABLE 80 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146.
TABLE 81 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 146.
TABLE 82 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 147.
TABLE 83 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2024–2031 (USD MILLION) 147.
TABLE 84 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 148.
TABLE 85 BRAZIL: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 149.
TABLE 86 MEXICO: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 150.
TABLE 87 REST OF LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 151.
TABLE 88 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 152.
TABLE 89 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 153.
TABLE 90 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 153.
TABLE 91 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2024–2031 (USD MILLION) 154.
TABLE 92 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 154.
TABLE 93 GCC COUNTRIES: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 155.
TABLE 94 REST OF MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 156.
TABLE 95 STRATEGIES ADOPTED BY PLAYERS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET 158.
TABLE 96 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DEGREE OF COMPETITION 161.
TABLE 97 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: REGION FOOTPRINT 166.
TABLE 98 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: TYPE FOOTPRINT 167.
TABLE 99 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: TYPE FOOTPRINT 168.
TABLE 100 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: PRODUCT TYPE FOOTPRINT 169.
TABLE 101 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: MODE FOOTPRINT 170.
TABLE 102 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: APPLICATION FOOTPRINT 171.
TABLE 103 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 174.
TABLE 104 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY PRODUCT TYPE 175.
TABLE 105 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY REGION 175.
TABLE 106 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2026 176.
TABLE 107 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DEALS, JANUARY 2021–JUNE 2026 177.
TABLE 108 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: EXPANSIONS, JANUARY 2021–JUNE 2026 178.
TABLE 109 WATERS CORPORATION: COMPANY OVERVIEW 181.
TABLE 110 WATERS CORPORATION: PRODUCTS OFFERED 182.
TABLE 111 WATERS CORPORATION: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2026 183.
TABLE 112 WATERS CORPORATION: DEALS, JANUARY 2022–JUNE 2026 183.
TABLE 113 WATERS CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2026 183.
TABLE 114 DANAHER CORPORATION: COMPANY OVERVIEW 185.
TABLE 115 DANAHER CORPORATION: PRODUCTS OFFERED 186.
TABLE 116 DANAHER CORPORATION: DEALS, JANUARY 2022–JUNE 2026 187.
TABLE 117 DANAHER CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2026 187.
TABLE 118 THERMO FISHER SCIENTIFIC INC: COMPANY OVERVIEW 189.
TABLE 119 THERMO FISHER SCIENTIFIC INC: PRODUCTS OFFERED 190.
TABLE 120 THERMO FISHER SCIENTIFIC INC: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2026 191.
TABLE 121 THERMO FISHER SCIENTIFIC INC: DEALS, JANUARY 2022-JUNE 2026 192.
TABLE 122 THERMO FISHER SCIENTIFIC INC: EXPANSIONS, JANUARY 2022–JUNE 2026 193.
TABLE 123 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 195.
TABLE 124 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 196.
TABLE 125 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2026 197.
TABLE 126 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022–JUNE 2026 197.
TABLE 127 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2022–JUNE 2026 198.
TABLE 128 SHIMADZU CORPORATION: COMPANY OVERVIEW 200.
TABLE 129 SHIMADZU CORPORATION: PRODUCTS OFFERED 201.
TABLE 130 SHIMADZU CORPORATION: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2026 202.
TABLE 131 SHIMADZU CORPORATION: DEALS, JANUARY 2022–JUNE 2026 203.
TABLE 132 SHIMADZU CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2026 203.
TABLE 133 BRUKER CORPORATION: COMPANY OVERVIEW 205.
TABLE 134 BRUKER CORPORATION: PRODUCTS OFFERED 206.
TABLE 135 BRUKER CORPORATION: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2026 207.
TABLE 136 BRUKER CORPORATION: DEALS, JANUARY 2022–JUNE 2026 208.
TABLE 137 BRUKER CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2026 208.
TABLE 138 METTLER TOLEDO: COMPANY OVERVIEW 209.
TABLE 139 METTLER TOLEDO: PRODUCTS OFFERED 210.
TABLE 140 METTLER-TOLEDO: DEALS, JANUARY 2022–JUNE 2026 211.
TABLE 141 CARL ZEISS AG (ZEISS GROUP): COMPANY OVERVIEW 212.
TABLE 142 CARL ZEISS AG (ZEISS GROUP): PRODUCTS OFFERED 213.
TABLE 143 CARL ZEISS AG (ZEISS GROUP): DEALS, JANUARY 2022–JUNE 2026 214.
TABLE 144 PERKINELMER: COMPANY OVERVIEW 215.
TABLE 145 PERKINELMER: PRODUCTS OFFERED 216.
TABLE 146 PERKINELMER: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2026 217.
TABLE 147 TABLE 17 PERKINELMER: DEALS, JANUARY 2022–JUNE 2026 217.
TABLE 148 EMERSON ELECTRIC CO: COMPANY OVERVIEW 218.
TABLE 149 EMERSON ELECTRIC CO: PRODUCTS OFFERED 219.
TABLE 150 EMERSON ELECTRIC CO: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2026 220.
TABLE 151 ABB: COMPANY OVERVIEW 221.
TABLE 152 ABB: PRODUCTS OFFERED 222.
TABLE 153 ABB: EXPANSIONS, JANUARY 2022–JUNE 2026 223.
TABLE 154 SARTORIUS AG: COMPANY OVERVIEW 224.
TABLE 155 SARTORIUS AG: PRODUCTS OFFERED 225.
TABLE 156 SARTORIUS AG: DEALS, JANUARY 2022–JUNE 2026 226.
TABLE 157 SARTORIUS AG: EXPANSIONS, JANUARY 2022–JUNE 2026 227.
TABLE 158 MERCK KGAA: COMPANY OVERVIEW 228.
TABLE 159 MERCK KGAA: PRODUCTS OFFERED 229.
TABLE 160 MERCK KGAA: DEALS, JANUARY 2022–MAY 2026 230.
TABLE 161 VERUM ANALYTICS: COMPANY OVERVIEW 231.
TABLE 162 VERUM ANALYTICS: PRODUCTS OFFERED 231.
TABLE 163 PROCESS INSIGHTS, INC: COMPANY OVERVIEW 232.
TABLE 164 PROCESS INSIGHTS, INC: PRODUCTS OFFERED 232.
TABLE 165 HAMILTON COMPANY: COMPANY OVERVIEW 233.
TABLE 166 ENDRESS+HAUSER GROUP SERVICES AG: COMPANY OVERVIEW 234.
TABLE 167 VIAVI SOLUTIONS INC: COMPANY OVERVIEW 235.
TABLE 168 METROHM AG: COMPANY OVERVIEW 236.
TABLE 169 CONTROL DEVELOPMENT, INC: COMPANY OVERVIEW 237.
TABLE 170 SCHMIDT + HAENSCH: COMPANY OVERVIEW 238.
TABLE 171 SENSUM D.O.O: COMPANY OVERVIEW 239.
TABLE 172 AMETEK, INC: COMPANY OVERVIEW 240.
TABLE 173 NECI: COMPANY OVERVIEW 241.
TABLE 174 SENTRONIC GMBH: COMPANY OVERVIEW 242.
FIGURE 1 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY (PAT) MARKET SEGMENTATION AND REGIONAL SCOPE 25.
FIGURE 2 YEARS CONSIDERED 27.
FIGURE 3 MARKET SCENARIO 29.
FIGURE 4 GLOBAL BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, 2024–2031 29.
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, 2023–2025 30.
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET 31.
FIGURE 7 HIGH-GROWTH SEGMENTS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, 2026–2031 32.
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET DURING FORECAST PERIOD 33.
FIGURE 9 INCREASING ADOPTION OF REAL-TIME PROCESS MONITORING AND QBD DRIVES BIOPHARMACEUTICAL PAT MARKET GROWTH 34.
FIGURE 10 BIOSIMILARS & BIOLOGICS TO BE LARGEST SEGMENT IN 2031 35.
FIGURE 11 ANALYZERS SEGMENT AND US ACCOUNTED FOR LARGEST MARKET SHARE IN 2O25 36.
FIGURE 12 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 37.
FIGURE 13 ASIA PACIFIC REGION TO DOMINATE MARKET DURING FORECAST PERIOD 38.
FIGURE 14 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 40.
FIGURE 15 IMPACT OF PORTER’S FIVE FORCES ON BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET 46.
FIGURE 16 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: SUPPLY CHAIN ANALYSIS 50.
FIGURE 17 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: VALUE CHAIN ANALYSIS 51.
FIGURE 18 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: ECOSYSTEM ANALYSIS 53.
FIGURE 19 AVERAGE SELLING PRICE OF BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGIES, BY REGION, 2025 (USD THOUSAND) 55.
FIGURE 20 IMPORT SCENARIO FOR HS CODE 902720, 2021–2025 (USD MILLION) 56.
FIGURE 21 EXPORT SCENARIO FOR HS CODE 902720, 2021–2025 (USD MILLION) 57.
FIGURE 22 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 60.
FIGURE 23 FUNDING SCENARIO AND NUMBER OF DEALS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, 2019–2023 61.
FIGURE 24 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 61.
FIGURE 25 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 (USD MILLION) 61.
FIGURE 26 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: PATENT ANALYSIS, 2015–2026 68.
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT TYPE 80.
FIGURE 28 KEY BUYING CRITERIA IN BPAT MARKET, BY PRODUCT TYPE 81.
FIGURE 29 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY (PAT) MARKET SNAPSHOT 120.
FIGURE 30 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SNAPSHOT 135.
FIGURE 31 REVENUE ANALYSIS OF TOP PLAYERS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, 2022–2025 160.
FIGURE 32 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 160.
FIGURE 33 RANKING OF KEY PLAYERS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, 2025 162.
FIGURE 34 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 164.
FIGURE 35 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPANY FOOTPRINT 165.
FIGURE 36 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 173.
FIGURE 37 EV/EBITDA OF KEY VENDORS 179.
FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 179.
FIGURE 39 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: BRAND/PRODUCT COMPARISON 180.
FIGURE 40 WATERS CORPORATION: COMPANY SNAPSHOT 182.
FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT 186.
FIGURE 42 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT 190.
FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 196.
FIGURE 44 SHIMADZU CORPORATION: COMPANY SNAPSHOT 201.
FIGURE 45 BRUKER CORPORATION: COMPANY SNAPSHOT 206.
FIGURE 46 METTLER-TOLEDO: COMPANY SNAPSHOT 210.
FIGURE 47 CARL ZEISS AG (ZEISS GROUP): COMPANY SNAPSHOT 213.
FIGURE 48 EMERSON ELECTRIC CO: COMPANY SNAPSHOT 219.
FIGURE 49 ABB: COMPANY SNAPSHOT 222.
FIGURE 50 SARTORIUS AG: COMPANY SNAPSHOT 225.
FIGURE 51 MERCK KGAA: COMPANY SNAPSHOT 229.
FIGURE 52 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: RESEARCH DESIGN METHODOLOGY 244.
FIGURE 53 PRIMARY SOURCES 246.
FIGURE 54 KEY INDUSTRY INSIGHTS 247.
FIGURE 55 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 247.
FIGURE 56 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 248.
FIGURE 57 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 249.
FIGURE 58 MARKET SIZE ESTIMATION FOR BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY (PAT) MARKET: APPROACH 1 (COMPANY REVENUE ESTIMATION) 250.
FIGURE 59 BOTTOM-UP APPROACH FOR MARKET SIZE ESTIMATION: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY (PAT) MARKET 251.
FIGURE 60 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 252.
FIGURE 61 DATA TRIANGULATION METHODOLOGY 253.